secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001641172-25-022971
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q2 revenue $63.7M (+30% YoY); net income $5M; VEVYE on track for >$100M; adds Samsung Bioepis
--------------------------------------------------------------------------------

- Total revenues $63.7M, up 30% YoY; GAAP net income $5.0M vs loss of $6.5M; Adj EBITDA $17.0M (up from $8.8M).
- VEVYE dry eye revenue on track to exceed $100M in 2025; Q2 market share 7.8%; 66% sequential prescription growth.
- IHEEZO revenue $18.3M (+62% YoY, +251% QoQ); TRIESENCE added 870 new accounts YTD; unit growth 32% QoQ.
- Secured exclusive U.S. rights to Samsung Bioepis ophthalmic biosimilars (BYOOVIZ, OPUVIZ) in July 2025.
- Acquired U.S. rights for BYQLOVI (clobetasol) in June 2025; Apollo Care alliance to expand VEVYE access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225022971/0001641172-25-022971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225022971/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer